Table 3.
Symmetry analysis of daridorexant 50 mg and 100 mg, and zopiclone vs. placebo
| Contrast | Day |
Impaired n (%) |
Improved n (%) |
Neutral n (%) |
McNemar χ2 | P value |
|---|---|---|---|---|---|---|
| Zopiclone vs. placebo |
2 5 |
35 (62.5) 28 (50.0) |
3 (5.4) 7 (12.5) |
18 (32.1) 21 (37.5) |
26.95 12.60 |
< 0.0001 0.0005 |
| Daridorexant 50 mg vs. placebo |
2 5 |
24 (43.6) 15 (25.9) |
8 (14.5) 16 (27.6) |
23 (41.8) 27 (46.6) |
8.00 0.03 |
0.0070 1.00 |
| Daridorexant 100 mg vs. placebo |
2 5 |
38 (65.5) 14 (24.1) |
4 (6.9) 7 (12.1) |
16 (27.6) 37 (63.8) |
27.52 2.33 |
< 0.0001 0.19 |
Impaired subject = subject with increase in SDLP from corresponding treatment over placebo > 2.6 cm; Improved subject = subject with decrease in SDLP from corresponding treatment over placebo < −2.6 cm.
SDLP, standard deviation of the lateral position.